Filter your results
- 4
- 4
- 4
- 1
- 1
- 2
- 4
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 4
- 4
- 4
- 4
- 4
- 3
- 3
- 3
- 3
- 3
- 3
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccinationJournal of Experimental Medicine, 2023, 220 (1), pp.e20220258. ⟨10.1084/jem.20220258⟩
Journal articles
pasteur-03847416v1
|
||
|
X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19Science Immunology, 2021, 6 (62), ⟨10.1126/sciimmunol.abl4348⟩
Journal articles
hal-03367639v1
|
||
|
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deathsScience Immunology, 2021, 6 (62), pp.eabl4340. ⟨10.1126/sciimmunol.abl4340⟩
Journal articles
hal-03358792v1
|
||
|
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodiesProceedings of the National Academy of Sciences of the United States of America, 2022, 119 (21), pp.349-363. ⟨10.1073/pnas.2200413119⟩
Journal articles
hal-03856619v2
|